Effect of Endurox on Exercise Time to Fatigue, Recovery, and Recovery Exercise Performance

2004 ◽  
Vol 36 (Supplement) ◽  
pp. S174
Author(s):  
John L. Bergen ◽  
Kyle O. McDaniel ◽  
Kristie Willhoit ◽  
Kat Caballero-Smith ◽  
Heidi Hebert
Keyword(s):  
Exercise Performance ◽  
Exercise Time ◽  
Recovery Exercise ◽  
Fatigue Recovery

scholarly journals Effect of Endurox on Exercise Time to Fatigue, Recovery, and Recovery Exercise Performance

2004 ◽  
Vol 36 (Supplement) ◽  
pp. S174
Author(s):  
John L. Bergen ◽  
Kyle O. McDaniel ◽  
Kristie Willhoit ◽  
Kat Caballero-Smith ◽  
Heidi Hebert
Keyword(s):  
Exercise Performance ◽  
Exercise Time ◽  
Recovery Exercise ◽  
Fatigue Recovery

Niacin supplementation impairs exercise performance

2021 ◽  
Author(s):  
Greggory R. Davis ◽  
Arnold G. Nelson
Keyword(s):  
Body Weight ◽  
Resistance Exercise ◽  
Aerobic Exercise ◽  
Exercise Performance ◽  
Respiratory Exchange Ratio ◽  
Time To Exhaustion ◽  
Total Work ◽  
Cycling Exercise ◽  
Exercise Time ◽  
Performance Effects

Abstract. Several pre-workout supplements contain niacin, although the exercise performance effects of niacin are poorly understood. The purpose of the present study was to examine the performance effects of niacin versus caffeine as a pre-workout supplement. Twenty-five untrained males were recruited to complete three identical ramped aerobic cycling exercise trials. Participants were administered caffeine (CA) at 5 mg/kg body weight, 1000 mg niacin (NI), or a methylcelluloce placebo (PL) supplement prior to each trial. NI treatment induced significantly higher respiratory exchange ratio (RER) during exercise compared to the CA treatment, but not the PL treatment (PL=0.87±0.08, NI=0.91±0.08, CA=0.87±0.08; p=0.02). Similarly, exercise time to exhaustion (in minutes) was significantly different between the NI treatment and the CA treatment, but not the PL treatment (PL=27.45±4.47, NI=26.30±4.91, CA=28.76±4.86; p<0.01). Habitual caffeine use (p=0.16), habitual aerobic exercise (p=0.60), and habitual resistance exercise (p=0.10) did not significantly affect RER. Similarly, habitual caffeine use (p=0.72), habitual aerobic exercise (p=0.08), and habitual resistance exercise (p=0.39) did not significantly affect total work performed. The elevated RER and decreased time to exhaustion in the NI treatment suggests limited lipid availability during exercise and impaired exercise performance.

scholarly journals Effects of Self-Myofascial Released and Sports Massage on Exercise Performance and Fatigue Recovery in Male College Students

2017 ◽  
Vol 26 (3) ◽  
pp. 179-187 ◽  
Author(s):  
Yang-Jung Kim ◽  
Sang-Hyun Lee ◽  
Su-Jin Kim ◽  
Hyo-Bum Kwak ◽  
Ju-Hee Kang ◽  
...  
Keyword(s):  
College Students ◽  
Exercise Performance ◽  
Male College ◽  
Fatigue Recovery ◽  
Male College Students

P5383Autologous adipose-derived stromal cell treatment for patients with refractory angina (MyStromalCell Trial) - 3-years follow-up results

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
A A Qayyum ◽  
A B Mathiasen ◽  
S Helqvist ◽  
E Joergensen ◽  
M H Haack-Soerensen ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Placebo Group ◽  
Exercise Performance ◽  
Left Ventricular Ejection ◽  
Refractory Angina ◽  
Bicycle Exercise ◽  
Exercise Time ◽  
Cardiac Symptoms

Abstract Background Improvements in medical and interventional therapies have transformed ischemic heart disease into a chronic illness for lot of patients. The disease is in progress and by time patients suffer from cardiac symptoms, reduced work capacity and decline in quality of life. Stem cell therapy is investigated as a treatment option for these patients. Purpose In this study, long-term safety and efficacy of autologous intra-myocardial injections of adipose-derived stromal cells (ASCs) were studied in patients with refractory angina. Methods Sixty patients were double-blinded 2:1 randomised to ASC or saline injections and followed for three years. The patients had significant angina due to ≥1 coronary artery stenosis but preserved left ventricular ejection fraction. ASCs were obtained from abdomen, ex vivo culture expanded and VEGF-A165 stimulated before delivery into the ischemic myocardium. Results The cardiac symptoms, CCS and NYHA classification, were significantly reduced in the ASC group during the three years follow-up period (2.5±0.9 to 1.8±1.2, P=0.002 and 2.4±0.6 to 2.2±0.8, P=0.007, respectively). However, no significant change was observed in CCS or NYHA in the placebo group during the follow-up period (2.5±0.8 to 2.1±1.3, P=0.186 and 2.7±0.6 to 2.4±0.8, P=0.314, respectively). Moreover, the number of weekly angina attacks reported was significantly reduced in the ASC group (P=0.017), but not in the placebo group (P=0.425). For patients in the ASC group, the bicycle exercise time (383±30s to 370±44s, P=0.052) and the exercise performance in watt were un-changed (81±6 to 78±10, P=0.123), but the performance in METs was reduced significantly (4.2±0.3 to 4.0±0.4, P=0.027) during the follow-up period. At the same time in the placebo group, there was a significant decline in bicycle exercise time (437±53s to 383±58s, P=0.001), the exercise performance measured in watt (87±12 watt to 80±12 watt, P=0.019) and in METs (4.5±0.4 to 4.1±0.4, P=0.002). In both groups, significant improved quality-of-life, angina stability, angina frequency and physical limitation score was observed but not for overall satisfaction score. Conclusion Patients receiving ASCs had improved cardiac symptoms during the three years follow-up period, which was not the case for patients in the placebo group. Moreover, patients receiving ASCs had unchanged exercise capacity, in opposition to deterioration in the placebo group. Acknowledgement/Funding Arvid Nilssons Foundation; Rigshospitalets Research Foundation; Aase and Ejnar Danielsens Foundation

Effect of Glycine Propionyl-L-Carnitine on Aerobic and Anaerobic Exercise Performance

2008 ◽  
Vol 18 (1) ◽  
pp. 19-36 ◽  
Author(s):  
Webb A. Smith ◽  
Andrew C. Fry ◽  
Lesley C. Tschume ◽  
Richard J. Bloomer
Keyword(s):  
Exercise Performance ◽  
Aerobic Training ◽  
Vastus Lateralis ◽  
Anaerobic Power ◽  
Anaerobic Exercise ◽  
Aerobic Exercise Training ◽  
Double Blind ◽  
Exercise Time ◽  
And Training ◽  
Aerobic And Anaerobic

The purpose of this study was to evaluate the effect of glycine propionyl-Lcarnitine (GPLC) supplementation and endurance training for 8 wk on aerobicand anaerobic-exercise performance in healthy men and women (age 18–44 yr). Participants were randomly assigned to 1 of 3 groups: placebo (n = 9), 1 g/d GPLC (n = 11), or 3 g/d GPLC (n = 12), in a double-blind fashion. Muscle carnitine (vastus lateralis), VO2peak, exercise time to fatigue, anaerobic threshold, anaerobic power, and total work were measured at baseline and after an 8-wk aerobic-training program. There were no statistical differences (p > .05) between or within the 3 groups for any performance-related variable or muscle carnitine concentrations after 8 wk of supplementation and training. These results suggest that up to 3 g/d GPLC for 8 wk in conjunction with aerobic-exercise training is ineffective for increasing muscle carnitine content and has no significant effects on aerobic- or anaerobic-exercise performance.

Exercise V˙e and physical performance at altitude are not affected by menstrual cycle phase

1999 ◽  
Vol 86 (5) ◽  
pp. 1519-1526 ◽  
Author(s):  
Beth A. Beidleman ◽  
Paul B. Rock ◽  
Stephen R. Muza ◽  
Charles S. Fulco ◽  
Vincent A. Forte ◽  
...  
Keyword(s):  
Menstrual Cycle ◽  
Sea Level ◽  
Exercise Performance ◽  
Minute Ventilation ◽  
Submaximal Exercise ◽  
Cycle Phase ◽  
Time To Exhaustion ◽  
Menstrual Cycle Phase ◽  
Exercise Time ◽  
Midluteal Phase

We hypothesized that progesterone-mediated ventilatory stimulation during the midluteal phase of the menstrual cycle would increase exercise minute ventilation (V˙e; l/min) at sea level (SL) and with acute altitude (AA) exposure but would only increase arterial O2 saturation ([Formula: see text], %) with AA exposure. We further hypothesized that an increased exercise[Formula: see text] with AA exposure would enhance O2 transport and improve both peak O2 uptake (V˙o 2 peak; ml ⋅ kg−1 ⋅ min−1) and submaximal exercise time to exhaustion (Exh; min) in the midluteal phase. Eight female lowlanders [33 ± 3 (mean ± SD) yr, 58 ± 6 kg] completed aV˙o 2 peak and Exh test at 70% of their altitude-specificV˙o 2 peak at SL and with AA exposure to 4,300 m in a hypobaric chamber (446 mmHg) in their early follicular and midluteal phases. Progesterone levels increased ( P < 0.05) ∼20-fold from the early follicular to midluteal phase at SL and AA. PeakV˙e (101 ± 17) and submaximalV˙e (55 ± 9) were not affected by cycle phase or altitude. Submaximal[Formula: see text] did not differ between cycle phases at SL, but it was 3% higher during the midluteal phase with AA exposure. NeitherV˙o 2 peak nor Exh time was affected by cycle phase at SL or AA. We conclude that, despite significantly increased progesterone levels in the midluteal phase, exercise V˙e is not increased at SL or AA. Moreover, neither maximal nor submaximal exercise performance is affected by menstrual cycle phase at SL or AA.

scholarly journals Autologous adipose-derived stromal cell treatment for patients with refractory angina (MyStromalCell Trial): 3-years follow-up results

2019 ◽  
Vol 17 (1) ◽  
Author(s):  
Abbas Ali Qayyum ◽  
Anders Bruun Mathiasen ◽  
Steffen Helqvist ◽  
Erik Jørgensen ◽  
Mandana Haack-Sørensen ◽  
...  
Keyword(s):  
Placebo Group ◽  
Exercise Performance ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Refractory Angina ◽  
Bicycle Exercise ◽  
Ventricular Ejection Fraction ◽  
Exercise Time ◽  
Cardiac Symptoms

Abstract Background Stem cell therapy is investigated as a treatment option for patients with ischemic heart disease. In this study, long-term safety and efficacy of autologous intra-myocardial injections of adipose-derived stromal cells (ASCs) was studied in patients with refractory angina. Methods Sixty patients with coronary artery stenosis and preserved left ventricular ejection fraction were 2:1 randomised to intramyocardial injections of ASCs or saline and followed for 3 years. Results For patients in the ASC group, the bicycle exercise time and the exercise performance in watt were un-changed (383 ± 30 s to 370 ± 44 s, P = 0.052 and 81 ± 6 to 78 ± 10, P = 0.123, respectively), but the performance in METs was reduced significantly (4.2 ± 0.3 to 4.0 ± 0.4, P = 0.027) during the follow-up period. However, in the same period, there was in the placebo group a significant decline in bicycle exercise time (437 ± 53 s to 383 ± 58 s, P = 0.001), the exercise performance measured in watt (87 ± 12 W to 80 ± 12 W, P = 0.019) and in METs (4.5 ± 0.4 to 4.1 ± 0.4, P = 0.002). Moreover, angina measured as CCS class was significantly reduced in the ASC group but not in the placebo group (2.5 ± 0.9 to 1.8 ± 1.2, P = 0.002 and 2.5 ± 0.8 to 2.1 ± 1.3, P = 0.186, respectively). However, no significant change was observed between the two groups. Conclusions Patients receiving ASCs had improved cardiac symptoms and unchanged exercise capacity, in opposition to deterioration in the placebo group. Trial registration ClinicalTrials.gov Identifier: NCT01449032. Registered 7 October 2011—Retrospectively registered, https://www.clinicaltrials.gov/ct2/show/NCT01449032?term=jens+kastrup&rank=7

Sign in / Sign up

Export Citation Format

Share Document